Anastrozol-Teva is a common part of endocrine therapy used to treat hormone-receptor-positive (HR+) breast cancer specifically in postmenopausal women. This medication is applied across conditions relevant in conditions characterized by periods of heightened symptoms, and is used in situations involving certain distressing symptoms to help manage the condition. It is commonly used for managing early breast cancer in the adjuvant setting, treating locally advanced disease, and plays a role as a therapeutic option for metastatic cancer.

The medication is commonly used as adjuvant treatment following initial surgery, where this usage is relevant for managing the long-term risk of disease recurrence and the potential for a new cancer to develop in the opposite breast. This contributes to easing the overall symptom load related to the condition's management. In advanced scenarios, Anastrozol-Teva is utilized in managing more challenging forms of the disease, playing a role in managing disease activity and may assist with maintaining functional stability during the necessary chronic care.

“This medication is applied across therapeutic domains involving heightened systemic burden and contributes to improved comfort during periods of symptomatic management.”

---

Quick Fact: Supportive Symptom Management

Anastrozol-Teva is relevant for easing symptoms that are linked to organ-specific functional stress caused by the malignancy, and its use assists with maintaining functional stability when symptoms interfere with routine activities.

Anastrozol-Teva is approved for use exclusively in postmenopausal women. The officially documented eligibility rules define several absolute exclusions and conditional restrictions based on physiological status, age, and pre-existing medical conditions.

Official Eligibility Exclusions

Population Status	Regulatory Classification
Premenopausal women	Contraindicated
Pregnant or Lactating women	Contraindicated
Known hypersensitivity to the active substance or excipients	Contraindicated
Children and Adolescents	Not Recommended (Safety not established)

The medicine is strictly contraindicated for all women who are premenopausal, pregnant, or breastfeeding, as defined in regulatory labeling. Absolute non-eligibility also applies to patients with specific hereditary disorders, such as galactose intolerance or Lapp lactase deficiency, due to the presence of excipients.

Conditional Use (Use with Caution)

Use requires caution in certain groups due to limited safety data. Administration must be performed with caution in patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 mL/min), as these populations have not been fully investigated in clinical breast cancer studies. The medicine is, however, considered eligible for use in older adults with no need for a dosage adjustment.

Interactions with other medicines and products

The interaction profile for Anastrozol-Teva is defined by specific combinations that must be avoided, as well as documented evidence of low risk for other common co-administered medicines, all based on official government regulatory information.

---

Formally Contraindicated Co-administrations

Co-administration with the following substances is officially contraindicated or must be avoided due to a potential antagonistic effect or a significant reduction in Anastrozole exposure:

• Estrogen-containing therapies: This includes estrogen replacement therapy (HRT) and oral contraceptives, as their co-administration can counteract the intended action of Anastrozole.
• Tamoxifen: The co-administration of Tamoxifen is documented to reduce the plasma concentration of Anastrozole by approximately 27%, which necessitates avoidance of this combination.

---

Pharmacokinetic and Exposure Considerations

Substance / Condition	Official Regulatory Finding
Warfarin	No clinically significant effect on the pharmacokinetics or anticoagulant activity of Warfarin was found.
Antipyrine	Anastrozole did not significantly inhibit the metabolism of Antipyrine, suggesting a low likelihood of clinically significant CYP-mediated interactions with most other medicines.
Food Intake	Food does not affect the extent of Anastrozole's absorption.
Bisphosphonates	No clinically significant interactions were identified in clinical trials.

---

Population-Specific Interaction Notes

• Hepatic Impairment: Caution is advised in patients with moderate or severe hepatic impairment. Exposure (AUC) to Anastrozole can be increased in subjects with stable hepatic cirrhosis.
• Severe Renal Impairment: Caution is advised in patients with severe renal impairment (GFR < 30 mL/min). Administration should be performed with caution in this patient population.

Targeted Inhibition of the Aromatase Enzyme

Anastrozol-Teva is designed to act on a specific enzyme called aromatase (CYP19A1), which is widely distributed in peripheral tissues throughout the body. The drug works as a competitive inhibitor, reversibly binding to the enzyme's active site, specifically the heme component. This targeted interaction directly blocks the enzyme's ability to perform its function, which is the final chemical step in the body's natural synthesis of estrogens from other precursor hormones.

---

Modulation of Systemic Estrogen Levels

The direct inhibition of the aromatase enzyme initiates a cascade that alters the body's hormonal environment. By preventing the conversion of androgens into estrogens in non-ovarian tissues, the drug leads to a substantial and continuous reduction of circulating estrogen (estradiol and estrone) concentrations. This reduction in estrogen represents a core physiological change, limiting the growth signal delivered to estrogen-responsive processes.

---

Molecular Blockade to Cellular Environment Modulation

The mechanistic cascade translates the molecular binding event into a large-scale biological response. The resulting scarcity of estrogen creates a new hormonal state where estrogen-dependent cellular activity is limited. This mechanism modulates the continuous signaling driven by the hormone, contributing to an environment that does not support the proliferation of estrogen-responsive cells.

How to Use Anastrozol-Teva

Anastrozol-Teva is an oral medicine with a standardized, fixed dosing regimen. Proper administration, dose, and frequency are essential for the therapeutic application of this medication.

Administration Details

Detail	Instruction
Route of Administration	Oral (by mouth) as a film-coated tablet.
Standard Daily Dose	1 mg (one tablet). This is the standard and maximum recommended dose.
Dosing Frequency	Once a day (daily).
Timing with Food	May be taken with or without food.
Tablet Preparation	The tablet should be swallowed whole with water.
Duration of Use	Typically 5 years for adjuvant use, or continued until tumor progression for advanced disease.

Population-Specific Guidelines

The 1 mg dose is applied across different clinical scenarios for specific patient populations:

• Older Adults: No dose adjustment is required for geriatric patients.
• Renal Impairment: No dose change is required for patients with mild or moderate kidney impairment. Caution is advised for those with severe impairment.
• Hepatic Impairment: No dose change is required for mild liver disease. Caution is advised for those with moderate to severe impairment.
• Use Restriction: The medicine is strictly for use in postmenopausal women. This status must be confirmed before treatment initiation.

Missed Dose: If a patient forgets a dose, they should take the next tablet at the usual scheduled time. Doubling the dose to compensate for a missed one is not recommended.

Research evidence / Overview of studies for Anastrozol-Teva

Evidence for Use as Adjuvant Therapy in Early Breast Cancer

The research for this medicine includes large-scale, international, randomized controlled trials (RCTs). These studies were applied in research contexts involving postmenopausal women who had already completed initial treatment for hormone-receptor-positive breast cancer. Researchers explored how outcomes related to disease recurrence would evolve over time, using long periods of observation. These trials were designed to compare the use of this medicine against a previous hormonal treatment, tamoxifen.

These studies monitored specific disease endpoints, primarily Disease-Free Survival (DFS) and Time to Recurrence (TTR). Findings describe measured patterns observed in the studies, where outcomes related to recurrence and the incidence of a new primary cancer in the opposite breast were measured across the two groups. Studies monitored how these measured differences evolved over long periods of observation, including the time after the active treatment ended. However, even with extensive long-term tracking, the studies monitored differences in Overall Survival (OS) that appeared similar between the two treatment groups across the full ten-year follow-up period.

Evidence for Use in Advanced or Metastatic Breast Cancer

Anastrozole was evaluated in randomized, comparative studies for locally advanced or metastatic breast cancer. These trials observed Anastrozole both as a first-line treatment and in patients whose condition had progressed following prior hormonal treatment. Research reports that the measured Time to Progression (TTP) was observed to be either similar to or, in some studies, different from the TTP reported for the tamoxifen comparison arm. When used as a second-line option, Anastrozole was studied for its ability to achieve comparable objective response rates when measured against existing second-line agents.

Evidence Gaps and Areas of Ongoing Research

While the medicine has a significant foundation in large-scale randomized trials, certainty remains low in several areas, as is common in medical research. Long-term effects are not fully established for all potential non-recurrence related health issues, and this information is still emerging from extended follow-up studies. Comparative evidence is more limited regarding the newest sequential endocrine treatments and combination therapies.

Common questions about Anastrozol-Teva (FAQ)

Q: What is Anastrozol-Teva and what is it used for?

Anastrozol-Teva is a medicine that belongs to a group of drugs called aromatase inhibitors. It works by blocking the enzyme aromatase, which helps produce the female sex hormone estrogen in the body, particularly in postmenopausal women. The reduction of estrogen can slow or stop the growth of certain types of breast cancer that are sensitive to this hormone.

It is used to treat hormone receptor-positive early breast cancer in postmenopausal women, and to treat advanced breast cancer in postmenopausal women.

---

Q: How should I take Anastrozol-Teva?

The usual dose is one 1 mg tablet taken once a day. You should try to take your tablet at the same time each day.

• The tablets should be swallowed whole with a drink of water.
• It can be taken with or without food.

Follow your doctor's instructions exactly. The duration of treatment can be long-term, potentially for five years or more, depending on your condition and response to treatment. Do not stop taking the medicine without talking to your doctor first.

---

Q: What are the common side effects of Anastrozol-Teva?

Like all medicines, Anastrozol-Teva can cause side effects, although not everybody gets them. The most common side effects are often related to the reduction of estrogen levels, similar to symptoms experienced during menopause.

Very common side effects (may affect more than 1 in 10 people) include:

• Hot flushes
• Joint pain or stiffness
• Feeling sick (nausea)
• Headache

Common side effects (may affect up to 1 in 10 people) include:

• Tiredness (fatigue)
• High blood pressure
• Thinning of the bones (osteoporosis) which may lead to fractures
• Vomiting or diarrhoea
• Rash, including a type of rash called urticaria
• Changes in blood tests for liver function

It is important to tell your doctor or pharmacist about any side effect you experience, especially if it is severe or persistent.

---

Q: Can I take Anastrozol-Teva if I have liver or kidney problems?

Your doctor should be informed if you have moderate to severe liver problems or if you have any degree of kidney problems. Although dose adjustments are generally not required for mild-to-moderate liver disease or kidney impairment, your doctor may need to monitor you more closely.

Anastrozol-Teva has not been studied in women with severe liver disease.

---

Q: What should I do if I miss a dose?

If you forget to take a tablet, simply take the next dose as usual at the scheduled time. Do not take a double dose to make up for a forgotten dose.

If you are unsure or miss several doses, contact your doctor or pharmacist for advice.

How to Store and Dispose of Anastrozol-Teva?

The official storage guidelines for Anastrozol-Teva tablets focus on maintaining product stability and ensuring safety. The medication must be kept at room temperature, specifically below 30 C (86 F), and kept away from excess moisture and direct light. The film-coated tablets should remain in their original, tightly closed container or blister pack until administration to preserve packaging integrity.

Mandatory Safety and Disposal Rules

Requirement	Official Rule
Child Safety	Keep out of the sight and reach of children.
Disposal	Do not dispose of via wastewater or household waste.

Unused or expired medicine must be discarded according to local regulatory requirements to comply with environmental protection standards.